ENXTPA:ALECR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. More Details


Snowflake Analysis

Solid track record with excellent balance sheet.

Share Price & News

How has Eurofins-Cerep's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: Insufficient data to determine ALECR's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine ALECR's volatility change over the past year.


Market Performance


7 Day Return

-19.1%

ALECR

-5.0%

FR Life Sciences

1.1%

FR Market


1 Year Return

54.0%

ALECR

62.0%

FR Life Sciences

-2.6%

FR Market

Return vs Industry: ALECR underperformed the French Life Sciences industry which returned 60.6% over the past year.

Return vs Market: ALECR exceeded the French Market which returned -3% over the past year.


Shareholder returns

ALECRIndustryMarket
7 Day-19.1%-5.0%1.1%
30 Day29.1%-6.0%15.2%
90 Dayn/a-0.4%11.6%
1 Year54.0%54.0%62.8%62.0%-0.6%-2.6%
3 Year59.2%59.2%123.0%117.9%16.8%7.1%
5 Year92.9%92.9%232.3%211.0%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is Eurofins-Cerep's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eurofins-Cerep undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Eurofins-Cerep is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Eurofins-Cerep has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Eurofins-Cerep forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eurofins-Cerep has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Eurofins-Cerep performed over the past 5 years?

20.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALECR has high quality earnings.

Growing Profit Margin: ALECR's current net profit margins (17.9%) are higher than last year (10.6%).


Past Earnings Growth Analysis

Earnings Trend: ALECR's earnings have grown significantly by 20.8% per year over the past 5 years.

Accelerating Growth: ALECR's earnings growth over the past year (109.8%) exceeds its 5-year average (20.8% per year).

Earnings vs Industry: ALECR earnings growth over the past year (109.8%) exceeded the Life Sciences industry 30.1%.


Return on Equity

High ROE: ALECR's Return on Equity (18.4%) is considered low.


Next Steps

Financial Health

How is Eurofins-Cerep's financial position?


Financial Position Analysis

Short Term Liabilities: ALECR's short term assets (€34.9M) exceed its short term liabilities (€7.6M).

Long Term Liabilities: ALECR's short term assets (€34.9M) exceed its long term liabilities (€2.5M).


Debt to Equity History and Analysis

Debt Level: ALECR's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: ALECR's debt to equity ratio has reduced from 0.6% to 0.01% over the past 5 years.

Debt Coverage: Insufficient data to determine if ALECR's debt is well covered by operating cash flow.

Interest Coverage: ALECR's interest payments on its debt are well covered by EBIT (127.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Eurofins-Cerep current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALECR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALECR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALECR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALECR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALECR's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average board tenure


CEO

Antoine Duthilleul

2.58yrs

Tenure

Antoine Duthilleul has been Managing Director and Director at Eurofins Cerep SA since April 19, 2018. He has been President of The Eurofins Discovery Products France at Eurofins-Cerep SA since February 28,...


Board Members

NamePositionTenureCompensationOwnership
Antoine Duthilleul
MD, Director & President of The Eurofins Discovery Products France2.58yrsno datano data
Damien Seroux
Chairman2.58yrsno datano data
Christina Shasserre
Director5.42yrsno datano data

2.6yrs

Average Tenure

Experienced Board: ALECR's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eurofins-Cerep SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eurofins-Cerep SA
  • Ticker: ALECR
  • Exchange: ENXTPA
  • Founded: 1989
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €48.170m
  • Shares outstanding: 5.04k
  • Website: https://www.eurofins.fr/cerep

Number of Employees


Location

  • Eurofins-Cerep SA
  • Le Bois l'Evêque
  • Celle L'Evescault
  • Vienne
  • Poitou-Charentes
  • 86600
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALECRENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 2015

Biography

Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company’s research services include compound management, high-throughput screening, i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 18:56
End of Day Share Price2020/11/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.